<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00319865</url>
  </required_header>
  <id_info>
    <org_study_id>KMM55</org_study_id>
    <nct_id>NCT00319865</nct_id>
  </id_info>
  <brief_title>PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>PS-341 (Bortezomib, Velcade®), Adriamycin and Dexamethasone (PAD) Combination Therapy Followed by Thalidomide With Dexamethasone (Thal/Dex) for Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korean Multiple Myeloma Working Party</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Korean Multiple Myeloma Working Party</source>
  <brief_summary>
    <textblock>
      Prospective multicenter phase 2 study using PAD and Thal/Dex combination sequentially.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although the overall survival was improved with the introduction of high dose therapy with
      autologous hematopoetic stem cell transplantation,it remains as a incurable disease. Most
      patients ultimately relapse. Recenlty, targeted therapy using novel agents, such as
      bortezomib and thalidomide, shows the possibility of improved in this situation. Among them,
      PAD (Velcade, Adriamycin,Dexamethasone) showed highest response rate. PAD does not show any
      cross resiatance with another effective combination, thalidomide plus dexamethasone.

      We desined prospective multicenter phase 2 study using these combination sequentially.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2005</start_date>
  <completion_date>September 2008</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate of PAD induction Therapy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate of PAD followed by Thal/Dex maintenance</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival and Overall survival of PAD/Thal-Dex.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate toxicities of PAD/Thal-Dex</measure>
  </secondary_outcome>
  <enrollment>47</enrollment>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Velcade</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adriamycin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with multiple myeloma who relapsed after at least 1 lines of therapy
             including high dose thearapy with autologous stem cell transplantation and
             chemotherapy.

          -  Presence of measureble disease : serum M-protein &gt; 1g/dL or urine M-protein &gt;
             400mg/day

          -  Age &lt; 75

          -  Performance status &lt;/= ECOG 2

          -  Expected survival &gt; 6 months

          -  who signs the informed consent

        Exclusion Criteria:

          -  known hypersensitivity to thalidomide or dexamethasone

          -  known refractoriness to thalidomide + dexamethasone

          -  Previous Velcade therapy

          -  Sepsis

          -  Woman in reproductive age

          -  Serum creatinine &gt; 2 mg/dL ; 24 hour creatinine clearance &lt; 30 ml/min; past medical
             history of kidney transplatation

          -  Peripheral neuropathy &gt;/= grade 2

          -  Recurrent DVT or pulmonary embolism

          -  Cardiac ejection fraction &lt;0.5 : Severe conduction disorder

          -  Hepatic dysfunction (AST or ALT ≥ x 5 upper normal) or active hepatitis

          -  Active ulcers in gastrofiberscope
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae Hoon Lee, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korean Multiple Myeloma Working Party</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jae Hoon Lee, M.D.</last_name>
    <phone>82-32-460-2186</phone>
    <email>jhlee@gilhospital.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hee Keun Kang, R.N.</last_name>
    <phone>82-32-460-3655</phone>
    <email>happy@gilhospital.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gachon University Gil Hospital</name>
      <address>
        <city>Inchon</city>
        <zip>405-220</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae Hoon Lee, M.D.</last_name>
      <phone>82-32-460-2186</phone>
      <email>jhlee@gilhoospital.com</email>
    </contact>
    <contact_backup>
      <last_name>Hee Keun Kang, R.N.</last_name>
      <phone>82-32-460-3655</phone>
      <email>happy@gilhospital.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jae Hoon Lee, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eun Mi Nam, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.hematology.or.kr/</url>
    <description>Korean Society of Hematology</description>
  </link>
  <verification_date>April 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2006</study_first_submitted>
  <study_first_submitted_qc>April 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2006</study_first_posted>
  <last_update_submitted>April 28, 2006</last_update_submitted>
  <last_update_submitted_qc>April 28, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2006</last_update_posted>
  <keyword>Multiple Myeloma Relapsed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

